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PERKAITAN DI ANTARA EKSPRESI PROTEIN DAN MRNA BAGI  PENINDAS 
TRANSKRIPSI DREAM, C-FOS DAN PRODYNORPHIN DALAM MEMINDA 
TINDAK BALAS KESAKITAN YANG DICETUSKAN OLEH FORMALIN DALAM 
KORDA SPINA TIKUS 
 
 
ABSTRAK 
 
Protein Downstream Regulatory Element Antagonist Modulator (DREAM) 
bertindak sebagai penindas transkripsi bagi gen c-Fos dan prodynorphin yang 
terlibat dalam proses kesakitan. Kajian ini dijalankan untuk mengesan perkaitan 
di antara ekspresi protein dan mRNA bagi DREAM, c-Fos dan prodynorphin di 
dalam meminda tindak balas kesakitan yang dicetuskan oleh formalin melalui 
reseptor opioid dan bukan-opioid dalam korda spina tikus. Tikus jantan Sprague 
Dawley seberat 250-350 g diagihkan kepada 5 kumpulan besar. Kumpulan 1 
mengandungi tikus yang dirawat dengan pemberian ketamin pra-emptif (drug 
anestetik) (5 mg/kg berat badan) secara intraperitoneum dan selepas 30 minit 
diberikan suntikan formalin (Kumpulan K+F) (n=36). Kumpulan 2 mengandungi 
tikus yang dirawat dengan pemberian norbinaltorphimine dihydrochloride 
(norBNI) pra-emptif (perencat reseptor kappa opioid) (2 mg/kg berat badan) 
secara intraperitoneum dan selepas 24 jam diberikan suntikan formalin 
(Kumpulan N+F) (n=36). Tikus dalam kumpulan 3 dirawat dengan pemberian 
ketamin dan norBNI pra-emptif, secara intraperitoneum dan diberikan suntikan 
formalin (Kumpulan NK+F) (n=36). Tikus dalam kumpulan 4 hanya dirawat 
dengan pemberian salin normal dan diberikan suntikan formalin (Kumpulan F) 
(n=36) manakala tikus dalam kumpulan 5 tidak diberikan sebarang rawatan dan 
dianggap sebagai kumpulan kawalan (Kumpulan C) (n=18). Setiap kumpulan 
kecuali kumpulan kawalan diagihkan kepada subkumpulan tikus (n=6) yang 
dibunuh pada 2 dan 4 jam selepas suntikan formalin. Lima peratus formalin 
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(1.85% larutan formaldehyde) dengan isipadu 50 µl disuntik secara subkutaneus 
pada permukaan plantar kaki belakang sebelah kiri tikus sebagai rangsangan 
kesakitan. Seterusnya, kelakuan tindak balas kesakitan direkodkan selama 1 jam 
untuk kumpulan F, K+F, N+F dan NK+F. Dua dan 4 jam selepas suntikan 
formalin, tikus dibunuh dan korda spina di bahagian segmen lumbar L4/L5 
dikeluarkan untuk analisis immunohistokimia, Western blot dan Real-Time PCR. 
Rangsangan kesakitan (suntikan formalin) dalam kajian ini meningkatkan jumlah 
bilangan neuron bagi FLI dan PLI selari dengan peningkatan aras relatif mRNA 
bagi c-Fos dan prodynorphin 2 jam selepas suntikan formalin di sisi ipsilateral. 
Purata aras relatif protein daripada ekstrak nukleus dan aras relatif mRNA bagi 
DREAM turut meningkat pada masa ini. Kesan ini berkemungkinan menyumbang 
kepada peningkatan kelakuan tindak balas kesakitan semasa fasa tonik ujian 
formalin. Walau bagaimanapun pemberian ketamin pra-emptif menghalang 
peningkatan jumlah bilangan neuron bagi FLI dan PLI serta aras relatif mRNA 
bagi c-Fos dan prodynorphin 2 jam selepas suntikan formalin di sisi ipsilateral. 
Kajian ini mendapati aras relatif mRNA bagi DREAM turut mengurang manakala 
aras purata relatif protein bagi DREAM daripada ekstrak nukleus meningkat pada 
masa yang sama. Kesan ini berkemungkinan menyumbang kepada pengurangan 
kelakuan tindak balas kesakitan semasa fasa tonik ujian formalin dalam 
kumpulan ini. Pemberian norBNI pra-emptif (perencat reseptor kappa opioid) 
meningkatkan jumlah bilangan neuron bagi FLI dan PLI selari dengan 
peningkatan aras relatif mRNA bagi c-Fos dan prodynorphin 2 jam selepas 
suntikan formalin di sisi ipsilateral. Kesan ini mengakibatkan pengurangan aras 
purata relatif protein bagi DREAM daripada ekstrak nukleus dan aras relatif 
mRNA bagi DREAM pada masa ini. Selanjutnya, pemberian norBNI pra-emptif 
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menggalakkan kelakuan tindak balas kesakitan semasa fasa tonik dalam ujian 
formalin. Pemberian ketamin dan norBNI pra-emptif menghilangkan sebahagian 
kesan pemberian pra-emptif bersendirian ketamin dan norBNI. Penemuan ini 
mencadangkan bahawa kedua-dua reseptor bagi NMDA dan kappa opioid 
terlibat dalam meminda proses kesakitan yang akut dalam kajian ini. Walau 
bagaimanapun perubahan ke atas protein dan mRNA bagi c-Fos dan DREAM 
tidak berpanjangan dan berbalik semula ke asal selepas 4 jam kecuali perubahan 
ke atas ekspresi protein dan mRNA bagi prodynorphin. Penemuan ini 
membuktikan bahawa ekspresi protein dan mRNA bagi prodynorphin adalah 
penting untuk mekanisma kesakitan yang berpanjangan. Aras purata relatif 
protein bagi DREAM daripada ekstrak sitoplasma tidak terjejas dalam setiap 
kumpulan eksperimen dalam kajian ini pada 2 dan 4 jam selepas suntikan 
formalin. Sebagai kesimpulan, kajian ini mencadangkan bahawa protein DREAM 
bertindak sebagai perencat transkripsi gen bagi  c-Fos dan prodynorphin dan 
boleh dipinda oleh tindakan reseptor bagi NMDA dan kappa opioid semasa 
kesakitan akut. Ini berkemungkinan dicapai melalui perubahan lokasi protein 
DREAM di dalam nukleus atau sitoplasma sel neuron. Proses penting ini 
membenarkan peningkatan atau pengurangan transkripsi gen c-Fos dan 
prodynorphin serta ekspresi proteinnya dalam korda spina tikus semasa proses  
kesakitan yang akut.   
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THE RELATIONSHIP BETWEEN PROTEIN AND MRNA EXPRESSION OF 
TRANSCRIPTION REPRESSOR DREAM, C-FOS AND PRODYNORPHIN IN 
MODULATING PAIN RESPONSES INDUCED BY FORMALIN IN THE RAT 
SPINAL CORD 
 
 
ABSTRACT 
 
Downstream Regulatory Element Antagonist Modulator (DREAM) protein 
acts as a transcription repressor for c-Fos and prodynorphin gene which is 
involved in modulating pain processes. This study was conducted to investigate 
the relationship between DREAM, c-Fos, prodynorphin protein and mRNA 
expression through opioid and non-opioid receptors in the modulation of pain 
responses induced by formalin in the rat spinal cord. Male Sprague Dawley rats 
weighing between 250-300 g were divided into five major groups. Group 1 
consisted of rats treated with pre-emptive administration of ketamine (anaesthetic 
drug) (5 mg/kg body weight) intraperitoneally (i.p) and given formalin injection 
(K+F group) (n =36), 30 minutes later. Group 2 consisted of rats treated with pre-
emptive administration of norbinaltorphimine dihydrochloride (norBNI) (kappa 
opioid receptor antagonist) (2 mg/kg body weight) i.p and given formalin injection 
(N+F group) (n = 36) after 24 hours. Rats in group 3 were treated with pre-
emptive administration of both ketamine and norBNI i.p and given formalin 
injection (NK+F group) (n=36). Rats in group 4 were only treated with normal 
saline and given formalin injection (F group) (n= 36) while rats in group 5 were 
not given any treatment and considered as a control group (C group) (n =18). 
Each experimental group except the control group was further divided into 
subgroups (n = 6) consisting of rats that were sacrificed at 2 and 4 hours after 
formalin injection. Fifty µl of formalin 5% (1.85% formaldehyde solution), was 
subcutaneously injected into the plantar surface of the left hind paw of the rat. 
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The pain behaviour responses were recorded for one hour for rats in the C, F, 
K+F, N+F and NK+F groups. The rats were then sacrificed 2 and 4 hours after 
formalin injection and the lumbar L4/L5 segments of spinal cords were removed 
for immunohistochemistry, Western blot and Real-Time PCR analysis. Noxious 
stimuli (formalin injection) in this study increased the total number of FLI and PLI 
neurons, consistent with an increase in relative c-Fos and prodynorphin mRNA 
levels at 2 hours after formalin injection on the ipsilateral side. The mean relative 
DREAM protein in the nuclear extract and relative DREAM mRNA levels were 
also increased at the same time. These effects probably contributed to increases 
in pain behaviour responses during the tonic phase of the formalin test. However, 
pre-emptive administration of ketamine prevented the increase of total number of 
FLI and PLI neurons and relative c-Fos and prodynorphin mRNA level at 2 hours 
after formalin injection on the ipsilateral side. At the same time, this study found 
that the relative DREAM mRNA level was decreased but the mean relative 
DREAM protein level in the nuclear extract was increased at this time. These 
effects may reduce pain behavior responses during the tonic phase of the 
formalin test in this group. Pre-emptive administration of norBNI (kappa opioid 
receptor antagonist) increased the total number of FLI and PLI neurons, 
consistent with the relative c-Fos and prodynorphin mRNA level at 2 hours after 
formalin injection on the ipsilateral side. These effects resulted in decreased 
mean relative DREAM protein level in the nuclear extract and relative DREAM 
mRNA level at this time. Furthermore, pre-emptive administration of norBNI 
enhanced pain behaviour responses during the tonic phase of the formalin test.  
Pre-emptive administration of both ketamine and norBNI eliminated some of the 
effects of pre-emptive administration of ketamine and norBNI. These findings 
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suggest that both NMDA and kappa opioid receptors are involved in modulating 
acute pain responses in this study. However, the changes in c-Fos and DREAM 
mRNA and protein expression at 2 hours are not prolonged and reverse to the 
basal state at 4 hours except for the changes in prodynorphin mRNA and protein 
expression. These findings suggest that prodynorphin mRNA and protein 
expression are important in persistent pain mechanisms. In addition, the mean 
relative DREAM protein in the cytoplasm extract was unaffected in each of the 
experimental groups in this study after 2 and 4 hours following formalin injection. 
In conclusion, this study shows that DREAM protein acts as a transcription 
repressor for c-Fos and prodynorphin gene and can be modulated by NMDA and 
kappa opioid receptor action during acute pain. The modulation is achieved 
through changes in the localization of DREAM protein in the nucleus or 
cytoplasm of neurons. This is an important mechanism which permits the 
upregulation and downregulation of c-Fos and prodynorphin gene and its protein 
expression in the rat spinal cord during acute pain processes.  
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CHAPTER 1 
             INTRODUCTION 
1.1 PAIN 
Pain is a universal phenomenon that affects millions of people around the 
world. Pain is a highly disagreeable sensation which results from a highly 
complex and interactive series of mechanisms integrated at all levels of the 
neuroaxis, from the periphery, via the dorsal horn to the higher cerebral 
structures (Millan, 1999). The International Association for the Study of Pain 
(IASP) defines pain as “An unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such 
damage” (Loeser and Melzack, 1999).  
 
Pain consists of two separate phenomena: physiological pain and 
pathological pain. Under normal circumstances, physiological pain occurs as a 
result of intense or potentially damaging noxious stimuli, which activates the 
nociceptors. It is highly localized and transient with the main purpose of informing 
the body of potential danger. On the other hand, pathological pain arises as a 
result of tissue or nerve damage. It persists long after healing of the damaged 
peripheral tissue has occurred and can lead to chronic pain. Pathological pain in 
its acute form is usually associated with tissue damage and inflammation 
(inflammatory pain) and has a protective function. In its chronic form, pathological 
pain is usually associated with nerve damage (neuropathic pain). In this case, the 
pain no longer has any adaptive function at all (Loeser and Melzack, 1999).  
 
 
 29 
1.2  PRIMARY AFFERENT FIBRES  
Pain is initiated by specialized primary afferent fibres (PAF) called sensory 
nociceptor fibres which innervate peripheral tissues in all regions of the head and 
body. These nociceptor fibres are activated only by noxious stimuli (painful) and 
have characteristic thresholds or sensitivities that distinguish them from other 
sensory nerve fibres. In general, PAF are categorized into three main groups 
based on their structure, diameter and conduction velocity (Julius and Basbaum, 
2001, Bessou et al., 1971). 
1) Polymodal nociceptors, consisting of C unmyelinated axons, thin, 0.4 
± 1.2mm  in diameter and slowly conducting at rates of 0.5 ± 2.0 m/s. 
2) High threshold mechanoreceptors, consisting of myelinated Aδ axons, 
2 ± 6 mm in diameter and conduct at rates of 12 ± 30 m/s. 
3) Aβ fibres, >10mm in diameter, myelinated and fast conducting at 
rates of 30 ± 100 m/s. 
 
The Aß-fibres detect innocuous stimuli (non-painful) and thus are not 
involved in pain processing (Djouhri et al., 1998). However, noxious stimuli from 
various kinds of stimuli (mechanical, thermal and chemical) are processed by 
thinly myelinated (Aδ-fibres) and unmyelinated (C-fibres) afferent fibres. The 
nociceptive transducer receptor/ion channel complexes that are present in the 
terminals of these nociceptive fibres become activated and convert the noxious 
stimuli into depolarizing currents (Woolf and Salter, 2000). Examples of 
transducer proteins that respond to extrinsic or intrinsic irritant chemical stimuli 
include vanilloid receptor (VR1), acid sensing ion channel subtype (DRASIC), G-
protein coupled  adenosine triphosphate (ATP) receptors and ATP-gated ion 
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channel (P2Y and P2X) receptors (Caterina et al., 1997). Transducers 
responsible for moderate thermal nociception are characterized by VR1 receptors 
and for high threshold heat responses are mediated by vanilloid receptor-like 
channel (VRL-1) receptors (Caterina et al., 1999). A transducer for noxious 
mechanical stimuli has not been identified, although studies suggest that it may 
belong to the acid sensing ion channel subtype of the degenerin family (MDEG) 
(Waldmann and Lazdunski, 1998).  
 
 Noxious stimuli initiate receptor potentials, which then lead to the initiation 
of a depolarizing current. When the depolarizing current is sufficient enough to 
reach threshold potential, an action potential is initiated. The activated thin 
myelinated Aδ or unmyelinated C-fibre then transmits this action potential from 
peripheral tissues to the spinal dorsal horn and then projects the action potential 
to the cerebral cortex to elicit the pain response (Julius and Basbaum, 2001). 
Stimulation of nociceptors will also activate the withdrawal reflex with an increase 
in arousal as well as emotional, autonomic and neurohumoral responses (Woolf 
and Salter, 2000). 
 
1.3 PERIPHERAL SENSITIZATION 
Under normal circumstances, nociceptor-mediated pain only occurs in 
response to high intensity noxious stimuli. Following peripheral tissue injury, the 
inflammatory reaction generates a complex set of chemical signals that alters the 
transduction properties of nociceptors such that they can be activated by low 
intensity stimuli. This phenomenon is known as peripheral sensitization. This 
mechanism is achieved partly from the production and release of chemical 
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mediators from primary sensory terminals and from non-neural cells (for example, 
fibroblasts, mast cells, neutrophils and platelets) (Figure 1.1)  (Woolf, 1991). 
Numerous chemicals that mediate or facilitate the pain process include 
bradykinin, prostaglandin, leukotriene, serotonin, histamine, substance P (SP), 
thromboxane, platelet-activating factor, adenosine and ATP, protons and free 
radicals. Cytokines, such as interleukins and tumour necrosis factor (TNF) and 
neurotrophins especially nerve growth factor (NGF), are also generated during 
pain processing (Meyer et al., 2006). Some of these agents can directly activate 
nociceptors, while others act indirectly through second messenger signalling 
cascades (Woolf and Salter, 2000). In addition, nociceptors that release SP and 
calcitonin gene-related peptide (CGRP) also induce vasodilation and plasma 
extravasations (leakage of protein and fluid from post-capillary venules) as well 
as activation of many non-neuronal cells, including mast cells and neutrophils. 
The variety of chemical mediators released during inflammation can have a 
synergistic effect in the potentiation of nociceptor responses (Meyer et al., 2006).  
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Figure 1.1: Potential peripheral mediators of peripheral sensitization after 
inflammation. Adapted from Woolf and Costigan, (1999). 
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1.4 PAIN PROCESSES IN THE SPINAL CORD 
1.4.1 Types of neurons in the spinal cord 
The dorsal horn of the spinal cord is the major receiving zone for PAF that 
transmits information from sensory receptors in the skin, viscera, joints and 
muscles of the trunk and limbs to the central nervous system. In the dorsal horn, 
PAF enter and ascend 1 or 2 segments in Lissauer’s tract, and terminate in the 
grey matter of the dorsal horn. Fibre terminations are segregated in laminae 
according to their functional properties (Cross, 1994). High threshold C and Aδ-
fibres terminate predominantly in laminae I, II and V, while low-threshold Aß 
mechanoreceptors terminate in deeper laminae (Willis, 2007). 
 
Neurons in the dorsal horn of the spinal cord can be divided into three 
general classes: projecting neurons, propriospinal neurons and local interneurons 
(Willis and Coggeshall, 1991). The projecting neurons are the second order 
nociceptive neurons with cell bodies in the dorsal horn and axons that terminate 
in the thalamus. There are generally two types of projecting neurons: nociceptive 
specific (NS) neurons which respond specifically to noxious stimuli and wide 
dynamic range (WDR) neurons which respond to both noxious and innocuous 
stimuli (Riedel and Neeck, 2001). NS neurons are mainly located in the 
superficial aspects of the dorsal horn, outer aspect of lamina II and in lamina V 
and VI while WDR neurons are located in the deep dorsal horn (lamina IV-V) 
(Willis, 2007). The axons of both types of neurons cross the midline within 1 or 2 
segments and ascend in the spinothalamic tract (STT) which is one of the major 
tracts involved in conveying nociceptive information to the higher centres.  
 
 34 
  The role of propriospinal neurons in nociception is poorly understood. 
However, it is known that these neurons are able to act as a multisynaptic 
pathway that transfers information to the brain. They have a major role in 
controlling locomotion and in organizing coordinated reflex responses while the 
majority of intrinsic dorsal horn neurons are local interneurons which send their 
axons for only a short distance within the spinal cord and comprise both 
excitatory and inhibitory interneurons (Powell and Todd, 1992).   
 
1.4.2 Central sensitization 
The activity-dependent alteration or plasticity in the dorsal horn neurons is 
termed central sensitization. Figure 1.2 outlines the mechanism of central 
sensitization where nociceptors respond in an abnormal or exaggerated way to 
afferent input (Ji et al., 2003, Woolf, 1991). When dorsal horn excitability is 
increased, their response to sensory input is facilitated or sensitized, producing a 
state of hypersensibility (Ji et al., 2003, Woolf and Salter, 2000). A low-intensity 
stimulus acting via low threshold afferents can now generate pain via a 
phenomenon known as allodynia, and noxious inputs result in a pain response 
that is augmented in amplitude (hyperalgesia) and duration (hyperpathia) 
(Koltzenburg et al., 1994). 
 
1.4.3 Synaptic transmission in the dorsal horn 
Several neurotransmitters are released for nociceptive transmission in the 
neuron at the dorsal horn of the spinal cord (Figure 1.2). There are excitatory 
amino acids (EAAs), e.g. glutamate and aspartate that are released from the 
terminals of primary afferents, intrinsic interneurons and projection fibres (Gilron 
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and Coderre, 1997). The effects of the EAA actions are mediated via both 
metabotrophic glutamate receptors (mGluRs) and ionotropic receptors on the 
postsynaptic neurons of the dorsal horn of the spinal cord (Kawasaki et al., 2004). 
There are three types of ionotropic receptors: 2-amino-3-hydroxy-5-methyl-4-
isoxazole-proprionic acid (AMPA), kainate (KA) and N-methyl-D-aspartate 
(NMDA) receptors (Dickenson and Sullivan, 1991). There are also a number of 
peptides involved in nociception, e.g. tachykinins (neurokinin A (NKA) and 
neurokinin B (NKB)), CGRP, somatostatin, gamma-aminobutyric acid (GABA), 
neurotensin, avian pancreatic peptide, cholecystokinin and neuropeptide Y 
(Cross, 1994).  Postsynaptic receptors, which bind tachykinins, are neurokinin-1 
(NK-1), neurokinin-2 (NK-2) and neurokinin-3 (NK-3) (Gilron and Coderre, 1997).  
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Figure 1.2: Central sensitization and synaptic transmission in the dorsal horn of 
the spinal cord. Adapted from Griffin and Woolf, (2005). 
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1.4.4 Ascending pathway 
The ascending pain pathway transmits nociceptive information from 
peripheral tissue to the cerebral cortex for interpretation. The classic ascending 
pain pathway is the spinothalamic tract (STT). The STT consists of a three 
neuron chain that transmits pain information form the periphery to the cerebral 
cortex via the thalamus (Figure 1.3) (Renn and Dorsey, 2005, Cross, 1994). The 
first order neuron has its cell body in the dorsal root ganglion with two axons, one 
extending distally to the tissue it innervates while the other extends proximally to 
the dorsal horn of the spinal cord. In the dorsal horn, this axon synapses with the 
second order neuron that in turn will cross the spinal cord through the anterior 
white commissure and ascends through the spinothalamic tract to the thalamus. 
The majority of the projection neurons that travel in the STT originate in the 
superficial laminae I and II and deeper laminae V of the spinal dorsal horn 
(Apkarian and Hodge, 1989). In the thalamus, the second order neuron synapses 
with the third order neuron, which ascends through the internal capsule and 
corona radiata to the postcentral gyrus of the cerebral cortex. This arrangement 
is call somatotopy (Windhorst, 1996). 
 
A second prominent ascending pathway is the spinomesencephalic tract 
(SMT), which originates in laminae I, II and V of the spinal dorsal horn, and 
travels in the ventrolateral funiculus (VLF) to the midbrain. Within the midbrain, 
the neurons in the SMT terminate in several areas, such as the periaqueductal 
grey (PAG) and nucleus cuneiformis (NCF) (Figure 1.3). A third tract that has 
also been shown to convey nociceptive in formation is the spinoreticular tract 
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(SRT) which terminates in the reticular formation of the medulla (Figure 1.3) 
(Renn and Dorsey, 2005).  
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Figure 1.3: Ascending pain pathways. The spinothalamic (STT, top), 
spinomesencephalic (SMT, bottom left) and spinoreticular (SRT, bottom right) 
tracts. Adapted from Dubner and Ren, (1999). 
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1.4.5 Descending pathway  
At the spinal cord, pain stimuli can be influenced by various endogenous 
mechanisms within the central nervous system both peripherally and centrally. 
These mechanisms can either be inhibitory or facilitatory (Millan, 2002, Dubner 
and Ren, 1999). 
 
The attenuation of afferent sensory nerve activity at peripheral nerve 
terminals can be achieved by a neuroimmune mechanism. Inflammation of 
peripheral tissues will result in the upregulation of opioid receptors at peripheral 
sensory nerves (Stein, 1995). This is due to the release of endogenous 
substances such as corticotrophin releasing hormone and cytokines, which cause 
the expression of opioid peptides by resident immune cells in inflamed peripheral 
tissue. Binding of opioids to opioid receptors brings about an increase in 
potassium currents and a decrease in Ca2+ currents in cell bodies of sensory 
neurons causing inhibition of neuronal firing and transmitter release. Opioids also 
inhibit Ca2+ dependent release of excitatory, proinflammatory compounds such as 
SP from peripheral sensory nerve endings (Stein, 1995). 
 
Central pain transmission is modulated by supraspinal sites via 
descending pathways and by segmental interneurons in the spinal cord (Millan, 
2002). The descending pathways originate from the cortex, thalamus and brain 
stem (Cross, 1994, Basbaum and Fields, 1984). Forebrain structures including 
the medial preoptic area, the amygdala, the insular cortex and the anterior 
cingular cortex (ACG) modulate activity at the brainstem level which in turn 
project to the dorsal horn of the spinal cord (Dubner and Ren, 1999). The brain 
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stem analgesic system and its descending projections to the dorsal horn 
constitute a powerful negative feedback system that is activated by nociceptive 
stimulation (through the spinoreticular, spinothalamic and spinocortical pathways). 
This in turn, produces inhibition of the spinal transmission of nociceptive signals 
(Cross, 1994). The brain stem structures involved in pain modulation include the 
PAG, the rostral ventromedial medulla (RVM) and the dorsolateral 
pontomesencephalic tegmentum (DLPT) (Figure 1.4) (Dubner and Ren, 1999). 
These structures receive inputs or afferents from the cortex, hypothalamus, 
amygdala and other brainstem areas including reticular formation, NCF, locus 
coeruleus, and spinal cord  (Millan, 2002). 
 
The transmitters involved in the descending modulation of pain are 
serotonin, adrenaline, noradrenaline and the opioids (Millan, 2002). Opioids act at 
various levels of the descending control system to inhibit spinal nociceptive 
transmission. Serotonin acting at the serotonergic receptor in the nucleus raphe 
magnus (NRM) has an inhibitory effect on dorsal horn nociceptive neurons while 
noradrenaline acting at alpha2-adrenergic receptors found at the locus coeruleus 
inhibits dorsal horn nociceptive transmission (Li and Zhuo, 2001).  
 
Segmental modulation occurs particularly at the spinal cord. The PAF (C, 
Aδ and Aß fibres) which terminate in the spinal cord can either directly stimulate 
projecting neurons (PN) which relay their messages to the brain, or indirectly 
engage PN to interneurons, which consist of excitatory and inhibitory 
interneurons. Descending pathways may then, modulate nociception via an 
interaction with several neuronal elements in the spinal cord dorsal horn  such as 
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the terminal endings of PAF, PN, excitatory and inhibitory interneurons and 
terminal endings of other descending pathways (Millan, 2002).  
 
Most inhibitory interneurons contain gamma-aminobutyric acid (GABA) 
and/or glycine as neurotransmitters. They synapse both presynaptically on PAF 
endings and postsynaptically on dorsal horn neurons (Powell and Todd, 1992). 
GABAergic cells make up approximately 25-30 % of the neurons in laminae I and 
II, and around 40% of those in lamina III (Todd and Sullivan, 1990). The inhibitory 
effects of GABA are mediated by two distinct classes of receptor, GABAA and 
GABAB (Desarmenien et al., 1983). GABA mediates presynaptic inhibition by 
reducing the release of excitatory neurotransmitter, e.g. glutamate, SP, CGRP 
which are involved in nociceptive transmission in the spinal cord (Malcangio and 
Bowery, 1994). This indirectly inhibits the activity of Aδ and C-fibres by activating 
the inhibitory interneurons or inhibiting the excitatory interneurons. This in turn 
decreases the level of nociceptive input to higher brain areas (Loeser and 
Melzack, 1999). The action of GABA at post-synaptic receptors produces 
hyperpolarization (Malcangio and Bowery, 1996). Loss of tonic GABAergic 
inhibition at the level of the spinal cord is one of the factors that lead to enhanced 
pain sensitivity observed in models of neuropathic pain states (Miletic et al., 
2003) while administration of GABA agonists reverse the mechanical allodynia 
observed in neuropathic rats (Malan et al., 2002).  
 
In addition to these descending inhibitory pathways, there are also 
descending facilitatory pathways which arise from the anterior cingulated cortex 
(ACC) and rostoventral medial medulla (RVM) (Robinson et al., 2004). ACC 
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activates the endogenous pain modulatory system due to its projecting 
connections to the PAG in the midbrain. Activation of ACC by electrical 
stimulation or chemical microinjection into ACC produces facilitation of spinal 
nociceptive reflexes (Calejesan et al., 2000). The descending facilitatory 
modulation from ACC is most likely to be conveyed through the RVM because 
blockade of activity in the RVM attenuates or abolishes the facilitation. The RVM 
contains the raphe nuclei, adjacent complex of reticular nuclei including nuclei 
raphe magnus (NRM), nucleus reticularis gigantocellularis (NRG), and nucleus 
gigantocellularis pars α (NGCα). Stimulation of different populations of neurons 
within the RVM can either activate or inhibit nociceptive transmission at the level 
of the dorsal horn (Zhuo and Gebhart, 1991). Lesions of the NGC inhibit 
secondary hyperalgesia produced by application of mustard oil, suggesting that 
this region is involved in facilitation during inflammatory hyperalgesia (Urban et 
al., 1996).  
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Figure 1.4: Descending pain pathways. Adapted from Dubner and Ren, (1999). 
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1.5 FORMALIN TEST 
There are many animal models of pain that have been constructed to 
enable the study of the different mechanisms and forms of pain. The formalin test 
involves the injection of dilute formalin either in one of the forepaws (Dubuisson 
and Dennis, 1977) or in one of the hindpaws (Abbadie et al., 1997) to elicit a 
nociceptive response. The hindpaw is usually chosen because it is rarely used 
during normal grooming behaviour, and thus may be more nociceptive-specific 
than the forepaw (Coderre et al., 1993).  
 
The formalin test is different from most models of pain. In this model, it is 
possible to assess the way an animal responds to moderate, continuous pain 
generated by injured tissue (Tjolsen et al., 1992).  Due to this connection to 
tissue injury, it is believed that the formalin test provides a more valid model for 
clinical pain as its tonic nature makes it resemble human postoperative pain more 
closely (Chen et al., 1989) than the tests with phasic mechanical or thermal 
stimuli.  
 
Pain behaviour after formalin injection can be separated into two distinct 
phases. The first phase starts immediately after injection of formalin and lasts for 
3-5 minutes. It is due to direct chemical stimulation of nociceptors (Dubuisson 
and Dennis, 1977) and predominantly evokes activity in C and not in Aδ fibres 
(Tjolsen et al., 1992). The second phase starts approximately 15-20 minutes after 
formalin injection and lasts for 20-40 minutes (Tjolsen et al., 1992). The injection 
of formalin into the hindpaw of rats increases Fos protein expression at L4/L5 
segmental levels of the spinal cord (Bon et al., 2002, Presley et al., 1990).  Fos 
